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Conventional solvent fractionation and bioactivity based target assays were used to identify a new anti-cancer molecule from
Phyllanthus urinaria, a herbal medicinal plant used in South India. At each step of the puriﬁcation process the different fractions
that were isolated were tested for speciﬁc anti-proliferative activity by assays measuring the inhibition of [
3H]thymidine
incorporation, and trypan blue drug exclusion. The ethyl acetate fraction that contained the bioactivity was further puriﬁed and
resolved by HPLC on a preparative column. The purity of each of the fractions and their bioactivity were checked. Fraction 3
demonstrated a single spot on TLC and showed maximum anti-proliferative activity. This fraction was further puriﬁed and the
structure was deﬁned as 7'-hydroxy-3',4',5,9,9'-pentamethoxy-3,4-methylene dioxy lignan using NMR and mass spectrometry
analysis. The pure compound and the crude ethyl acetate fraction which showed anti-proliferative activities were examined for
ability to target speciﬁc markers of apoptosis like bcl2, c-myc and caspases and for effects on telomerase. Four speciﬁc cancer
cell lines HEp2, EL-1 monocytes, HeLa and MCP7 were used in this study. The results indicate that 7'-hydroxy-3',4',5,9,9'-
pentamethoxy-3,4-methylene dioxy lignan was capable of inhibiting telomerase activity and also could inhibit bcl2 and activate
caspase 3 and caspase 8 whose signiﬁcance in the induction of apoptosis is well known. We believe that this compound could
serve as a valuable chemotherapeutic drug after further evaluations.
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Traditional herbs have been used as a valuable source of medi-
cines for the treatment of several diseases in many parts of the
world. In this study, we have examined the potential anti-cancer
property of Phyllanthus urinaria, which has been used for treat-
ment of jaundice, asthma and cancer (Mulchandani and
Hassarajani, 1984).
The role of apoptosis in cancers has been studied in detail,
apoptosis being a highly regulated cellular response with crucial
checkpoints regulating the fate of cells. These checkpoints are
processing centers sensing extracellular signals, amplifying localised
signals, integrating information from these cells and directing them
towards death cascade (Thompson, 1995). Several proto-oncogenes
such as c-myc, bcl2, c-fos (Evan et al, 1992) have been implicated as
active apoptotic effectors, while cH-ras and v-src are known to
modulate non-direct regulating interactions. Using these effectors
as targets for new drug development, several new compounds with
different chemical entities have been identiﬁed from medicinal
plants. A wide variety of natural substances have been recognised
to induce apoptosis in various tumour cells of human origin
(e.g., Liu et al, 2000).
The role of c-myc in apoptosis is highlighted in many human
cancers (Evan and Littlewood, 1998). The observation that c-myc
actively promotes apoptosis explains the potent cooperative effects
observed between c-myc and bcl2 (Strasser et al, 1990). One of the
targets of oncogene -induced sensitisation is the mitochondria and
c-myc facilitates cytochrome c release from the mitochondria (Juin
et al, 1999). The released cytochrome c activates caspases, a family
of cysteine proteases and bcl2 suppression thereby causing apopto-
sis. Senescence is an irreversible programme of cell cycle arrest that
is disturbed in many tumours or tumour derived cell lines (Barnett
et al, 1993). Owing to the end replication problem, telomeres
shorten during each cell division unless telomerase is expressed.
In cancers telomerase is found and is known to play a role in
the cancer cell to evade apoptosis (Kim et al, 1994; Broccoli et
al, 1995). The use of telomerase as a possible target for anticancer
drug development seems to be promising. The interplay between
telomerase and key players of the apoptotic cascade will provide
evidence of the possible mode of induction of cell death using
speciﬁc chemical entities.
In this paper, we have employed bioactivity-based assays to
identify anti-proliferative potential of the extracts of the medicinal
plant P. urinaria using simple in vitro methods. Bioassay-guided
fractionation has enabled us to obtain a pure compound with
anti-cancer activity. Its molecular structure was elucidated as 7'-
hydroxy-3',4',5,9,9'-pentamethoxy-3,4-methylenedioxylignan.
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Chemicals and reagents
All cell lines used in this study were obtained from ATCC. All
ﬁne chemicals were obtained from Sigma- Aldrich, St Louis,
MO, USA and USB, Cleveland, OH, USA. [
3H]thymidine was
obtained from Amersham, UK. MTS assay kit was procured from
Promega, USA. TRAP assay and Teloquant Kit were obtained
from Pharmigen, USA. Bcl2 antibody were obtained from Santa
Cruz Biotechnology, Inc. Santa Cruz, California and caspases 3
and 8 antibodies were obtained from BD PharMingen, USA. Phyl-
lanthus urinaria was obtained from South India. The species was
examined by a taxonomist to conﬁrm the same. Different batches
were obtained, processed and checked for similar proﬁle of the
extracts by TLC.
Solvent extraction
The dried plant powder (100 gram) of P.urinaria was extracted
with different solvents at room temperature, from non-polar to
polar solvents namely ethylene glycol, ethyl acetate, methanol and
water. Each of these extracts were concentrated in a rotatory
evaporator under reduced pressure, giving 2–3 gram of each indi-
vidual extracts. Ten mg of the dried powder from each of the
solvent extracts were reconstituted to 1 ml with the respective
solvents and they were serially diluted to 1:10, 1:50, and 1:100
of the original stock preparations for anti-proliferative studies.
Cell culture
HEp-2 (alveolar epithelial carcinoma cell line), MCF7 (Breast
cancer cell line), HeLa (Cervical cancer line) and EL-1 monocyte
cells were maintained in F-12 Dulbecco’s Modiﬁed Eagle Medium
(DMEM) supplemented with 10% serum amphotericin
(3 mgm l
71), gentamycin (400 mgm l
71), streptomycin
(250 mgm l
71), penicillin (250 units ml
71) in a carbon dioxide
incubator at 5% CO2.
[
3H]thymidine incorporation studies
[
3H]thymidine (1 mCi per 1 ml of medium) was added to the
medium in which the cell line was maintained, a day prior to
the addition of the extracts. The different solvent fractions were
added to the cells. In a six well plate 20 ml (10 mg ml
71) of sample
was added to all wells that contain 1 ml of medium. As controls
the same volume of the different solvents was added. Different
dilutions of 1:10, 1:50 and 1:100 of the ethyl acetate fraction
was also carried out. The cultures were trypsinised at the desired
time points, pelleted and washed sequentially with 10% and 5%
TCA and solubilised in 0.1 N NaOH and 0.025% SDS solution.
The radioactivity of the samples was measured in the WALLAC
1409 Liquid scintillation counter and expressed as CPM mg
71
protein.
Thin layer chromatography (TLC)
TLC analysis was done with each of the solvent extracts. Four types
of solvent systems were used: (a) 25% ethyl acetate in hexane, (b)
50% ethyl acetate in hexane, (c) 100% ethyl acetate and (d) 5%
methanol in ethyl acetate.
Northern analysis
HEp-2 cells were grown in six well plates for 24 h; mRNA was
extracted from the cells using 1 ml TriZol reagent followed by
chloroform-isopropanol extraction. Approximately 50 mg of the
RNA was denatured by heating at 658C for 10 min and loaded
on to a 1.2% formaldehyde-agarose gel and run at 100 V for
1 h. RNA was transferred to a nitrocellulose paper by upward
capillary transfer, UV cross-linked and stored at 48C until further
probing. Plasmids bearing DNA probes for the proto-oncogene
c-myc was gifted by Prof Peter Williams, Leicester University,
UK. DNA probes were used at 150 mgm l
71 of hybridisation buffer
and labelled with [
32P]dCTP using Rediprime kit (Amersham Life
Sciences).
Column chromatography
Column was packed with hexane using silica gel 100–200 mesh
size as a matrix, samples were loaded as dried slurry of silicagel
and the column was eluted with increasing concentration of ethyl
acetate and methanol to increase polarities. The ratio of material
loaded and silica gel was 1:20. The fractions were analysed by
pre-coated TLC plates (Merck) and spots were visualised by expo-
sure to iodine, UV and phosphomolybdic acid spray reagents. The
active fraction was further puriﬁed by reverse phase HPLC using
acetonitrile-water gradient system; the compounds were detected
by UV-detector at 260 nm. The purity of active compound was
established by TLC and HPLC.
Structural characterisation
The structure of the active compound was determined by
1H,
13C
and
1H-
13C COSY NMR spectroscopy and electrospray ionisation
mass spectrometry. The NMR experiments were done in CDCl3
solution and ESMS using acetonitrile-water spray condition. The
1H and
13C NMR data showed characteristic peaks for lignan skele-
tons and conﬁrmed presence of ﬁve OMe groups (d 3.7–
3.8 p.p.m., 56OCH3). The presence of methylenedioxy was due
to a signal at 5.10 p.p.m. The positioning of OMe groups in ring
B (lower ring) was ascertained by the coupling pattern in
1H
NMR data and comparisons in the repeated data of related lignans.
The mass spectra conﬁrmed elemental composition C24H32O8
(448). Full details of structural characterisation will be published
elsewhere (Figure 8).
Non isotopic telomeric repeat ampliﬁcation protocol
(TRAP) assay
Lysate preparation and the TRAP assay were performed as
described earlier (Kim and Wu, 1997). Brieﬂy, HEp-2 and EL1-
monocytes are lysed in 200 ml of ice-cold CHAPS lysis buffer. After
30 min of incubation on ice, the lysates were centrifuged at
14000 g for 60 min at 48C and the total protein concentration
of the supernatant standardised according to the Bradford method
(approximately 1 mg1ml
71). Six microlitres of supernatant were
used for the TRAP assays. After an initial incubation period
(308C for 30 min), telomerase products were ampliﬁed using TS
and RP primers (35 cycles at 948C for 30 s, 538C for 30 s and
728C for 30 s). Assay speciﬁcity was conﬁrmed by inclusion of
RNAase pre-incubation control step, and Taq inhibition was
checked by including the 36 bp internal control. Amplicons were
electrophoresed on a 12.5% non-denaturing polyacrylamide gel
(19:1) stained with ethidium bromide and analysed.
Tubulin assay
HEp-2 cells were exposed to both crude ethyl acetate fraction
(10 mgm l
71) and pure compound (4.46 mM) for 24 h. The treated
monolayers were ﬁxed with 3% paraformaldehyde in PBS for
30 min. The ﬁxed cells were then permeabilised with 0.1% Triton
X-100 in PBS at 48C for 5 min. The cells were washed three times
with PBS and treated with anti-tubulin antibody (dilution in PBS
1:200) and incubated at 378C for 30 min. The cells were then
blocked with 5% serum to avoid non-speciﬁc binding. The cells
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ted with secondary antibody to tubulin, FITC labelled antimouse
IgG for 30 min at 378C.
Immunoblot analysis
Total cell lysates were prepared as reported in our earlier work
(Narayanan et al, 2000). Proteins were separated on SDS 10%
polyacrylamide gel. The gel was transferred onto a nitrocellulose
membrane (Hybond C+, Amersham Life Sciences) at 220 mA for
3 h. The membrane was then washed three times with PBS and
blocking reagent (3% Skimmed Milk) was added and blocked
overnight at 48C. Blocking reagent was washed with PBS twice
for 5 min each and primary antibody was added (bcl2, caspase
3 and 8). One per cent BSA in PBS, 0.1% Tween 20 was added
to the blot along with the primary antibody (1:2000) and rocked
gently at room temperature for 1 h. The blot was washed three
times with PBS for 5 min each. Secondary antibody (1:5000)
in 1% BSA in PBS, 0.1% Tween 20 was allowed to hybridise
for 1 h at room temperature. The bands were detected using
the chromogenic substrate NBT-BCIP in alkaline phosphate
buffer.
Measurement of apoptosis by ﬂow cytometry
For ﬂow cytometric analysis 1.5610
6 cells were processed as
follows. Cells were lysed with 0.1% Triton X-100 and incubated
with 50 mgm l
71 RNase A for 30 min at 378C. Nuclear DNA
was stained with 50 mgm l
71 propidium iodide (PI) and cells were
analysed for DNA content in FACScan ﬂow cytometer equipped
with cell quest software (Becton Dickinson USA).
RESULTS
Extraction and column puriﬁcation
The various solvent extracts were collected and each fraction was
tested for bioactivity. The TLC analysis of all the different fractions
were run under conditions described. Figure 1A shows the TLC
analysis of each solvent extract.
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Figure 1 (A) Thin layer chromatography proﬁle of each of the solvent extracts. (1) Ethyl acetate extract (2) Ethylene glycol extract, (3) Acetone extract,
(4) Methanol extract, (5) Water extract. Products are resolved in 50% ethyl acetate and 50% methanol and visualised in UV at 260 nm and Iodine chamber.
(B) Anti-proliferative effect of the ethyl acetate extract on HEp-2 cells monitored by [
3H]thymidine incorporation at 1, 3 days and 6 days time points. Dif-
ferent dilutions of the same fractions were tested. Control is untreated cells. S. Cont, is solvent control. Values are mean+s.e. (means of three replicates).
(C) Flow cytometry analysis of HEp2 in control and treated cells with crude ethyl acetate extract (10 mgm l
71)a t7 2h .
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The different solvent extracts of P. urinaria were added to the cells
as described above. Thymidine incorporation studies between two
time points, day 1 and day 3, showed marked inhibition of prolif-
eration of HEp2 cells by the ethyl acetate extract. Hence we
followed the ethyl acetate extract for the various studies. When
the dilutions were increased the extent of inhibition of proliferation
was reduced in ethyl acetate extract. The maximum inhibition of
proliferation was seen in crude ethyl acetate extract at 100 mgm l
71
and in 10 mgm l
71 of medium (Figure 1B). The extracts of the
other solvents namely ethylene glycol, acetone, methanol and water
extracts were also tested, since the inhibition of proliferation was
maximum with ethyl acetate fractions, this was taken up for further
puriﬁcation.
Puriﬁcation of active fraction
Various concentrations of hydrocarbons was tested on the TLC,
for the best resolution. Hexane/ethyl acetate (3:1) gave good
separation. The above mentioned solvent system was used to elute
the active compound. The fraction was concentrated under
reduced pressure and the homogeneity of the compounds were
determined by TLC. In the C-18 HPLC column using similar
conditions as above, six fractions were obtained and purity was
checked by TLC (Figure 2A), Compound 3 showed maximum
activity on HEp2 cells in 24 h (Figure 2B). This fraction was
subjected to structural characterisation studies and the molecular
weight and structure of the lead compound was determined using
ESMS and NMR studies. The IC50 value of pure compound in
Hep2 cells was found to be 4.46 mM by establishing a concentra-
tion-dependence curve (data not shown). Therefore in all the
experiments performed with the pure compound, we used the
dose of 4.46 mM. The crude ethyl acetate extract (10 mgm l
71)
and pure compound (4.46 mM) also showed marked inhibition
on HEp2, HeLa, MCF-7 and EL1 monocyte cell lines (Figure
3). Both the puriﬁed compound and crude ethyl acetate extract
though cytotoxic to the above four cancer cell lines. However,
initial studies on normal human lymphocytes, did not show cyto-
toxic effects at the same doses which were used on cancer cell
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Figure 2 (A) Puriﬁcation of ethyl acetate fraction by HPLC, six peaks were obtained and they were analysed by TLC and visualised under UV at 260 nm.
(B) Growth inhibition studies of the six peaks on HEp2 cells by [
3H]thymidine incorporation . The cells were treated with 2 mgm l
71 of all peaks. Values are
mean+s.e. (means of three replicates). (C) Flow cytometry analysis of the HEp2 in control and treated cells with pure compound 4.46 mM (Peak 3) at 72 h.
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primary culture from normal biopsy samples from different
tissues.
Northern analysis
HEp-2 cells were treated with crude ethyl acetate fraction
(10 mgm l
71) and the puriﬁed compound (4.46 mM) for 24 h. c-
myc expression levels in the above two conditions were elevated
after 24 h of treatment (Figure 4).
Assessment of telomerase activity through TRAP assay
Telomerase activity was monitored in HEp-2 and EL1 monocytes
cell lines. On treatment with both crude ethyl acetate extract
(10 mgm l
71) and pure compound (4.46 mM), inhibition of telo-
merase activity after 12 h of treatment was noted. In case of
pure compound, telomerase inhibition was higher than crude ethyl
acetate extract (Figure 5). In the TRAP assay, activity of the telo-
merase enzyme was assessed with the help of a number of TRAP
products formed and also depends on the intensity of the band.
The puriﬁed compound caused a signiﬁcant decrease in the activity
of telomerase.
Tubulin assembly assay
7'-hydroxy-3',4',5,9,9'-pentamethoxy-3,4-methylene dioxy lignan
(4.46 mM) and crude ethyl acetate fraction (10 mgm l
71) promote
assembly of microtubules after 24 h in HEp2 cells. In immunohis-
tochemistry studies we found mitotic arrest, which are stained in
yellow shade (Figure 6).
Immunoblot analysis
The bcl2, a family of channel regulators, controls mitochondrial
permeability. In our Western blot analysis we found suppression
of bcl2 (Figure 7) expression upon addition of pure compound
(4.46 mM) and crude ethyl acetate extract (10 mgm l
71) after 36 h
as compared to untreated control cells. Subsequently we found
elevated level of expression of caspase 8 (Figure 7), which lead to
turn on procaspase 3 to active caspase 3 (Figure 7) in treated
HEp2 cells. Caspase 3 is an effector caspase that performs the
majority of protein cleavages associated with apoptosis.
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Figure 3 Anti-proliferative effect of the crude ethyl acetate fraction (10 mgm l
71) and pure compound (4.46 mM) on HEp2, MCF-7, EL1 monocytes and
HeLa cells at day 1 and day 2.
12 34
C-myc
Actin
Figure 4 Northern blot analysis of c-myc at 24 h. The cells were ex-
posed to the crude ethyl acetate extract (10 mgm l
71) (Lane 2); Pure com-
pound (4.46 mM) (Lane 3); The untreated cells as control (Lane 1) and
solvent control (Lane 4) showed no induction of c-myc mRNA. Actin
was used as house keeping.
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Apoptosis in the presence of both crude ethyl acetate extract and
pure compound has been conformed and quantitated by ﬂow cyto-
metry. A distinct sub-G1 peak is seen in apoptosis, which is due to
accumulation of dying cells with reduced amounts of DNA. Our
observations show that more than 60% of cells undergo apoptosis
after 72 h in HEp2 cells treated with 10 mg of crude ethyl acetate
extract per ml of medium (Figure 1C). In case of pure compound
(4.46 mM) more than 70% of cells were seen in A0 peak (Sub G1)
was obtained at 72 h (Figure 2C).
Structural characterisation
Based on the data generated by the proton, carbon and COSY
NMR spectroscopy and electroscopy ionisation mass spectroscopy
the structure of the active compound was identiﬁed as 7'-hydro-
xy-3',4',5,9,9'-pentamethoxy-3,4-methylene dioxy lignan with a
formula indicated in (Figure 8).
DISCUSSION
Disturbances in signal cascades lead to impairment of cellular func-
tions (Marks et al, 2000). Under the inﬂuence of a bacteria, virus
or mutations as in cancers, improper functioning of several signal
molecules has been reported. One of the major defects in cancers is
the lack of cells to be driven into the apoptotic mode, due to
malfunction of molecules like c-myc (Evan and Littlewood,
1998), ras (White et al, 1995), p53 (Soengas et al, 1999), bcl2
(Haldar et al, 1995), caspases (Schotte et al, 2001) and telomerase
(Shay and Bacchetti, 1997). Hence, it is thought that targeting such
molecules in a cancer may provide a new therapeutic strategy.
Traditional medicinal practices of several countries provided valu-
able leads from which new molecules have been derived and used
successfully for the treatment of cancers like etoposide (Karpinich
et al, 2002). Many of the current chemotherapeutic agents have
been obtained from plant sources (Cragg and Newman, 1999).
Our approach has been to exploit the knowledge of traditional
medicine practiced in South India to screen plants that have been
used for the treatment of cancers. The approach is to integrate
chemical extraction and puriﬁcation of the active molecule to iden-
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Figure 6 The immunohistochemistry of microtubule assembly shows mitotic arrest in HEp2 cells treated with crude ethyl acetate extract (10 mgm l
71)
and pure compound (4.46 mM)a t2 4h .
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Figure 5 Assessment of telomerase activity by TRAP assay at
12 h.7HEp-2 Untreated control (Lane 1), Treated with crude ethyl acet-
ate extract (10 mgm l
71) (Lane 2), Treated with pure compound
(4.46 mM) (Lane 3), Control untreated EL-1 monocytes (Lane 4). Treated
with crude ethyl acetate extract (10 mgm l
71) (Lane 5). Treated with pure
compound (4.46 mM) (Lane 6). RNAse treated (-ve)control (Lane 7). Pre
incubated at 958 C (Lane 8) and Marker (Lane 9).
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Figure 7 Western blot analysis to conﬁrm the activity of the apoptotic pathway via (A) bcl2 inhibition ; (B) caspase 8 activation and (C) activation of
caspase 3 during treatment with the both crude ethyl acetate extract (10 mgm l
71) (lane 2) and Pure compound (4.46 mM) (Lane 3), (Lane 1) is an un-
treated control cells at 36 h.
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known cellular targets that induce apoptosis. By this approach we
have been able to isolate and structural elucidate a lignan, 7'-
hydroxy-3',4',5,9,9'-pentamethoxy-3,4-methylene dioxy lignan from
Phyllanthus urinaria (Balakrishnan et al, 2000).
Thymidine incorporation studies have shown anti-proliferative
activities in the crude ethyl acetate fractions (Figure 1B) and also
puriﬁed compound (Figure 2B). Flow cytometry analysis of the
appearance of distinct sub-G1 peak was seen in the cells treated
either with the crude ethyl acetate extract or with the pure
compound as early as 48 h and 72 h, more than 70% of cells
undergo apoptosis (Figure 1C and 2C). Since apoptotic programme
can be manipulated to produce massive changes in cell death, the
genes and proteins controlling apoptosis are potential targets. In
instances where apoptosis is disabled by proto-oncogenes, agents
that disturb their anti-apoptotic function can produce remarkable
increases in cell death. The role of c-myc in apoptosis is well
known (Thompson, 1995). Replicating cells are known to maintain
high level of c-myc expression correlating with growth and onset of
apoptosis (Evan et al, 1992). Our results indicate that the both
crude ethyl acetate extract and pure compound were capable of
increasing the levels of expression c-myc (Figure 4), suggesting a
possibility of the induction of apoptosis. We have also conﬁrmed
the induction of apoptosis in HEp2 cells after treatment with crude
ethyl acetate extract and pure compound by Propidium iodide and
annexinV staining at 72 h (data not shown). It has been shown
earlier that c-myc enhances apoptosis in low concentrations of
survival factors or oxygen and following treatment with diverse
cytotoxic agents (Evan et al, 1992; Graeber et al, 1996). Although
the induction of apoptosis was studied in detail on HEp2 cells,
our results with other cell lines tested suggest that both crude ethyl
acetate fraction and the pure compound induced cell death as early
as 24 h after treatment (Figure 3), suggesting that inducing apop-
totic cascade may be a useful target in cancer cells for effective
therapeutic measures.
Preliminary results on tubulin during mitotic spindle formation
suggest that the pure compound, 7'-hydroxy-3',4',5,9,9'-penta-
methoxy-3,4-methylene dioxy lignan promotes the assembly of
tubulin (Figure 6) after 24 h of treatment of HEp2 cells. Although
it has long been argued that drugs that affect microtubule assembly
will be effective against tumours through the inhibition of mitosis,
all evidence suggest that 7'-hydroxy-3',4',5,9,9'-pentamethoxy-3,4-
methylene dioxy lignan brings about anti-tumour activity through
initiation of apoptosis in cycling cells. Similar effects are observed
in previously used agents like taxol, which promote tubulin assem-
bly and inhibit microtubule depolymerisation (Keqiang et al, 1998).
It is clear from our results that the above compound induces
apoptosis by bcl2 suppression and activation of caspases (Figure
7). Earlier studies have suggested that suppression of bcl2 activity
in cells and activation of caspases 3 and 8 is strictly associated with
apoptosis (Kang Boem Kown et al, 2001) The inhibition of telo-
merase by the pure compound may also drive the cells to the
apoptotic cascade. However, whether this is due to a direct effect
on telomerase will need to be conﬁrmed further, but the data on
other targets of apoptosis may indicate that there could be a possi-
ble correlation (Figure 5). In an earlier study c-myc over expression
upregulates telomerase activity in mouse embryonic ﬁbroblasts and
myeloid cells (Rachid et al, 2001). It appears that the whole process
of cell death induction by cytotoxic agents will require the assess-
ment of several closely associated targets in the death cascade.
Thus, the measure of telomerase activity alone might not be infor-
mative, and has to be studied along with other targets of cell death.
In conclusion, our studies highlight the ability of integrating
ethno-botanical leads, chemical isolation and cell signalling cascade
targets to screen and isolate molecules with potent anti-cancer
activities. This study also indicates that 7'-hydroxy-3',4',5,9,9'-
pentamethoxy-3,4-methylene dioxy lignan compound induces
apoptosis in a wide spectrum of cancer cell line, blocks known
anti-apoptotic and stimulates proapoptotic cascades. The possibi-
lity of this compound as an effective pharmaceutical product is
worth pursuing.
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